{
  "trial_id": "NCT04852887",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the U.S., authorization permitting release of personal health information.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "The patient must have an ECOG performance status of 0 or 1.",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "The tumor must be unilateral invasive adenocarcinoma of the breast on histologic examination.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Patient must have undergone axillary staging (sentinel node biopsy and/or axillary node dissection).",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "The following staging criteria must be met postoperatively according to AJCC 8th edition criteria: By pathologic evaluation, primary tumor must be pT1 (less than or equal to 2 cm).",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "The patient must have been determined to be ER and/or PgR positive assessed by current ASCO/CAP Guideline Recommendations for hormone receptor testing.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Patients may be premenopausal or postmenopausal at the time of study entry. For study purposes, postmenopausal is defined as: Age 56 or older with no spontaneous menses for at least 12 months prior to study entry; or a documented hysterectomy; or Age 55 or younger with no spontaneous menses for at least 12 months prior to study entry (e.g., spontaneous or secondary to hysterectomy) and with a documented estradiol level in the postmenopausal range according to local institutional/laboratory standard; or Documented bilateral oophorectomy.",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "The interval between the last surgery for breast cancer (including re-excision of margins) and study entry must be no more than 70 days.",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Bilateral mammogram or MRI within 6 months prior to study entry.",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Patients must be intending to take endocrine therapy for a minimum 5 years duration (tamoxifen or aromatase inhibitor).",
      "label": "met",
      "evidence": "unknown"
    }
  ],
  "exclusion": [
    {
      "criterion": "Definitive clinical or radiologic evidence of metastatic disease.",
      "label": "not_met",
      "evidence": "quote"
    },
    {
      "criterion": "pT2 - pT4 tumors including inflammatory breast cancer.",
      "label": "not_met",
      "evidence": "unknown"
    }
  ],
  "notes": "The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam.",
  "_meta": {
    "topic_id": "25",
    "trial_id": "NCT04852887",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}